In a Phase I first-in-human study, researchers reported that a peptide vaccine targeting six common mutant KRAS variants (mKRAS-VAX) generated durable T-cell responses in high-risk pancreatic cancer cohorts. Across 20 participants, adverse events were grade 1–2 and 18/20 (90%) developed significant mKRAS-specific T cell responses, with vaccine-induced clonotypes persisting for up to two years and no PDAC cases during a median 16.5-month follow-up.